Comments
Loading...
AstraZeneca Analyst Ratings and Price Targets | NASDAQ:AZN | Benzinga
AstraZeneca PLC has a consensus price target of $85.43 based on the ratings of 13 analysts. The high is $97 issued by Goldman Sachs on May 30, 2024. The low is $75 issued by Argus Research on August 29, 2022. The 3 most-recent analyst ratings were released by TD Cowen, Argus Research, and Goldman Sachs on August 12, 2024, May 30, 2024, and May 30, 2024, respectively. With an average price target of $92.33 between TD Cowen, Argus Research, and Goldman Sachs, there's an implied 25.55% upside for AstraZeneca PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
Argus Research
Goldman Sachs
BMO Capital
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for AstraZeneca
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 02/13/2025 | Buy Now | — | UBS | Matthew Weston12% | — | Upgrade | Neutral → Buy | Get Alert |
| 11/20/2024 | Buy Now | — | UBS | Matthew Weston12% | — | Upgrade | Sell → Neutral | Get Alert |
| 09/11/2024 | Buy Now | — | Erste Group | Hans Engel64% | — | Upgrade | Hold → Buy | Get Alert |
| 08/12/2024 | Buy Now | 29.17% | TD Cowen | Steve Scala67% | $90 → $95 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 15.58% | Argus Research | Jasper Hellweg68% | $80 → $85 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 31.89% | Goldman Sachs | Rajan Sharma24% | → $97 | Initiates | → Buy | Get Alert |
| 04/26/2024 | Buy Now | 11.5% | BMO Capital | Etzer Darout48% | $80 → $82 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | — | Deutsche Bank | Emmanuel Papada11% | — | Upgrade | Sell → Hold | Get Alert |
| 02/12/2024 | Buy Now | 8.78% | BMO Capital | Etzer Darout48% | $82 → $80 | Maintains | Outperform | Get Alert |
| 02/08/2024 | Buy Now | — | Deutsche Bank | Emmanuel Papadakis48% | — | Downgrade | Buy → Hold | Get Alert |
| 01/23/2024 | Buy Now | 15.58% | Morgan Stanley | Mark Purcell30% | → $85 | Initiates | → Overweight | Get Alert |
| 01/03/2024 | Buy Now | — | Jefferies | Peter Welford58% | — | Downgrade | Buy → Hold | Get Alert |
| 09/25/2023 | Buy Now | 8.78% | Jefferies | Peter Welford58% | $66.5 → $80 | Upgrade | Hold → Buy | Get Alert |
| 09/08/2023 | Buy Now | — | Erste Group | — | — | Downgrade | Buy → Hold | Get Alert |
| 08/01/2023 | Buy Now | 12.86% | BMO Capital | Etzer Darout48% | $81 → $83 | Maintains | Outperform | Get Alert |
| 05/26/2023 | Buy Now | 8.78% | Argus Research | Jasper Hellweg68% | $85 → $80 | Maintains | Buy | Get Alert |
| 04/13/2023 | Buy Now | 15.58% | Argus Research | Jasper Hellweg68% | $75 → $85 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | 11.5% | BMO Capital | Etzer Darout48% | → $82 | Initiates | → Outperform | Get Alert |
| 11/14/2022 | Buy Now | 7.42% | SVB Leerink | Andrew Berens48% | $78 → $79 | Maintains | Outperform | Get Alert |
| 11/11/2022 | Buy Now | 6.06% | SVB Leerink | Andrew Berens48% | $75 → $78 | Maintains | Outperform | Get Alert |
| 08/29/2022 | Buy Now | 1.98% | Argus Research | John Eade74% | → $75 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for AstraZeneca (AZN) stock?
The latest price target for AstraZeneca (NASDAQ:AZN) was reported by UBS on February 13, 2025. The analyst firm set a price target for $0.00 expecting AZN to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AstraZeneca (AZN)?
The latest analyst rating for AstraZeneca (NASDAQ:AZN) was provided by UBS, and AstraZeneca upgraded their buy rating.
When was the last upgrade for AstraZeneca (AZN)?
The last upgrade for AstraZeneca PLC happened on February 13, 2025 when UBS raised their price target to N/A. UBS previously had a neutral for AstraZeneca PLC.
When was the last downgrade for AstraZeneca (AZN)?
The last downgrade for AstraZeneca PLC happened on February 8, 2024 when Deutsche Bank changed their price target from N/A to N/A for AstraZeneca PLC.
When is the next analyst rating going to be posted or updated for AstraZeneca (AZN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AstraZeneca, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AstraZeneca was filed on February 13, 2025 so you should expect the next rating to be made available sometime around February 13, 2026.
Is the Analyst Rating AstraZeneca (AZN) correct?
While ratings are subjective and will change, the latest AstraZeneca (AZN) rating was a upgraded with a price target of $0.00 to $0.00. The current price AstraZeneca (AZN) is trading at is $73.55, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
